Skip to main navigation
Skip to search
Skip to main content
Prinses Máxima Centrum Home
Nederlands
English
Search content at Prinses Máxima Centrum
Home
Profiles
Research Groups
Equipment
Research output
Prizes
Activities
Press/Media
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Paul B. Chapman
, Axel Hauschild
, Caroline Robert
, John B. Haanen
, Paolo Ascierto
, James Larkin
, Reinhard Dummer
, Claus Garbe
, Alessandro Testori
, Michele Maio
, David Hogg
, Paul Lorigan
, Celeste Lebbe
, Thomas Jouary
, Dirk Schadendorf
, Antoni Ribas
, Steven J. O'Day
, Jeffrey A. Sosman
, John M. Kirkwood
,
Alexander M.M. Eggermont
Brigitte Dreno, Keith Nolop, Jiang Li, Betty Nelson, Jeannie Hou, Richard J. Lee, Keith T. Flaherty, Grant A. McArthur
Show 8 more
Show less
Research output
:
Contribution to journal
›
Article
›
peer-review
6888
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Improved survival with vemurafenib in melanoma with BRAF V600E mutation'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
BRAF V600E mutation
100%
Improved Survival
100%
Melanoma
100%
Vemurafenib
100%
Dacarbazine
60%
Response Rate
40%
Progression-free Survival
30%
Interim Analysis
30%
Confidence Interval
20%
Overall Survival
20%
Previously Untreated
20%
Metastatic Melanoma
20%
Adverse Events
10%
Body Surface Area
10%
Randomized Clinical Trial
10%
Disease Progression
10%
Diarrhea
10%
Twice Daily
10%
Nausea
10%
Squamous Cell Carcinoma (SqCC)
10%
Arthralgia
10%
Dose Adjustment
10%
Risk of Death
10%
Toxic Effects
10%
Duration of Response
10%
Rash
10%
Alopecia
10%
Phase II Clinical Trial
10%
PLX4032
10%
Keratoacanthoma
10%
Relative Reduction
10%
Phase 1 Clinical Trial
10%
Safety Monitoring
10%
Data Monitoring
10%
Monitoring Boards
10%
Raf Kinase Inhibitor Protein
10%
Medicine and Dentistry
Vemurafenib
100%
Melanoma
100%
Dacarbazine
54%
Progression Free Survival
27%
Interim Analysis
27%
Overall Survival
18%
Metastatic Melanoma
18%
Clinical Trial
9%
Adverse Event
9%
Randomized Clinical Trial
9%
Squamous Cell Carcinoma
9%
Disease Exacerbation
9%
Diarrhea
9%
Nausea
9%
Body Surface
9%
Exanthem
9%
Photosensitivity
9%
Toxicity
9%
Alopecia Mucinosa
9%
Keratoacanthoma
9%
B Raf Kinase Inhibitor
9%
Arthralgia
9%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
100%
Vemurafenib
100%
Dacarbazine
54%
Progression Free Survival
27%
Overall Survival
18%
Metastatic Melanoma
18%
Clinical Trial
9%
Disease Exacerbation
9%
Diarrhea
9%
Adverse Event
9%
Arthralgia
9%
Squamous Cell Carcinoma
9%
Nausea
9%
Randomized Clinical Trial
9%
Toxicity
9%
Alopecia
9%
Rash
9%
Photosensitivity
9%
Keratoacanthoma
9%
B Raf Kinase Inhibitor
9%